Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

455.17
Delayed Data
As of May 26
 -0.53 / -0.12%
Today’s Change
325.35
Today|||52-Week Range
464.40
+23.99%
Year-to-Date
Charting the Biotechs
May 26 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
May 24 / Zacks.com - Paid Partner Content
Regeneron Presents Positive Phase II Data on HoFH Candidate
May 25 / Zacks.com - Paid Partner Content
Merck Presents Phase II Data on Chronic Cough Candidate
May 23 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
May 25 / Zacks.com - Paid Partner Content
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
May 23 / Zacks.com - Paid Partner Content
Boston Common Asset Management, LLC Buys Sociedad Quimica Y Minera De Chile SA, Albem...
May 25 / GuruFocus News - Paid Partner Content
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
May 22 / Zacks.com - Paid Partner Content
Theravance/Mylan Presents Phase III Data on COPD Candidate
May 24 / Zacks.com - Paid Partner Content
Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session
May 22 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close455.70
Today’s open456.70
Day’s range453.35 - 459.25
Volume475,520
Average volume (3 months)909,118
Market cap$48.4B
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)+39.49%
Earnings growth (this year)+13.47%
Earnings growth (next 5 years)+26.00%
Revenue growth (last year)+18.44%
P/E ratio55.0
Price/Sales8.79
Price/Book10.86

Competitors

 Today’s
change
Today’s
% change
SHPGShire-7.64-4.13%
BAXBaxter International...-0.50-0.85%
ZTSZoetis Inc+0.03+0.05%
VRTXVertex Pharmaceutica...+1.32+1.11%
Data as of 4:14pm ET, 05/26/2017

Financials

Next reporting dateAugust 8, 2017
EPS forecast (this quarter)$3.18
Annual revenue (last year)$4.9B
Annual profit (last year)$895.5M
Net profit margin18.42%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts